Patents by Inventor Wishrawana Sarathi RATNAYAKE

Wishrawana Sarathi RATNAYAKE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating melanoma using an inhibitor of an atypical protein kinase C
    Patent number: 11065266
    Abstract: The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-? and/or PKC-?. Non-limiting examples of an inhibitor of PKC-? and/or PKC-? include ICA-1 and ACPD. The invention also provides PKC-? and/or PKC-? as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-? and/or PKC-?. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-? and/or PKC-? based on the levels and/or activity of PKC-? and/or PKC-? mRNA or protein in the melanoma cells from the subject are also provided.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 20, 2021
    Assignees: UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Mildred Enid Acevedo-Duncan, Wishrawana Sarathi Ratnayake, David A. Ostrov
  • Method of Treating Melanoma Using an Inhibitor of an Atypical Protein Kinase C
    Publication number: 20200022994
    Abstract: The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-? and/or PKC-?. Non-limiting examples of an inhibitor of PKC-? and/or PKC-? include ICA-1 and ACPD. The invention also provides PKC-? and/or PKC-? as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-? and/or PKC-?. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-? and/or PKC-? based on the levels and/or activity of PKC-? and/or PKC-? mRNA or protein in the melanoma cells from the subject are also provided.
    Type: Application
    Filed: August 28, 2019
    Publication date: January 23, 2020
    Inventors: Mildred Enid ACEVEDO-DUNCAN, Wishrawana Sarathi RATNAYAKE, David A. OSTROV